Evidence map›Paper›PMID 32205973›Full record

ArticleIndian journal of surgical oncology2020

Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancer-Our Experience from a Tertiary Care Center from Northeast India.

Joydeep Purkayastha, Jitin Yadav, Abhijit Talukdar, Gaurav Das, Niju Pegu, Srishti Madhav, Pritesh R Singh, Vinay Mamidala

Open access · greenAbstract read
In one paragraph

Article in Indian journal of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joydeep Purkayastha1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Jitin Yadav1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.ORCID 0000-0002-1556-7558
Abhijit Talukdar1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Gaurav Das1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Niju Pegu1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Srishti MadhavDepartment of Prosthodontics, Dental College, Azamgarh, India.
Pritesh R Singh1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Vinay Mamidala1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Bhubaneswar Borooah Cancer Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) is common in the northeast and southern parts of India. Radical surgery is the cornerstone of treatment and offers the only chance for cure. This study was conducted to assess the outcomes of all resectable gastric cancers that presented to our tertiary cancer center in Northeast India. All patients undergoing upfront surgery for gastric cancer with curative intention between 2012 and 2017 were included in the study. A total of 116 patients who underwent upfront radical gastrectomy were included in the study. Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years (range 26-89). The most common mode of presentation was pain abdomen (53.8%). The most common location of tumor was the distal part (81%) followed by the proximal part (10.3%). The most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. Fifty-four patients received adjuvant chemotherapy while 32 patients received adjuvant chemoradiation (CTRT). At a median follow-up of 14 months (range, 2-78 months), overall 5-year survival was 23.75% (mean survival 33.77 months, median survival 24 months). The 5-year survival for stages I-III was 100%, 26.25%, and 11.25%, respectively (

Indexed as

ACCORD 07 trialD2 lymph node dissectionGastrectomyMAGIC trialPerioperative chemotherapy

Identifiers

PMID32205973
PMCPMC7064675
OpenAlexW2987066160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.